Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here…
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here…
A CDSCO expert panel recommended a Phase I trial of Indian Immunologicals' live attenuated Zika vaccine, developed with Griffith University and funded by ICMR.
PMV Pharmaceuticals' rezatapopt produced a 48% response rate in platinum-resistant ovarian cancer with TP53 Y220C in the pivotal PYNNACLE trial, with an FDA filing planned…
Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with…
Up to 15 people have died and more than 300 have sought care in Imphal after drinking spurious liquor in Manipur's Chandel district. What we…
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn…
FHD-909 discontinued: Foghorn and Lilly will not advance the SMARCA2 inhibitor after Phase 1 data, and Foghorn is cutting about 40% of its workforce.
Survodutide weight loss reached up to 13.1% versus 3.1% on placebo at 76 weeks in the Phase III SYNCHRONIZE-2 trial in people with type 2 diabetes.
Trevogrumab added to semaglutide cut lean muscle loss in Regeneron's nearly 1,000-patient trial, preserving over 70% of thigh muscle at 52 weeks.
Yutrepia patent ruling: a Delaware court found Liquidia's Yutrepia infringes two valid United Therapeutics patent claims, and Liquidia shares plunged.
FOR IMMEDIATE RELEASE — September 30, 2026 | Source: Acumen Research and Consulting Global Artificial Organs Market to Reach USD 63.31 Billion by 2035, Growing at 8.2% CAGR The global…
The U.S. Food and Drug Administration has granted Premarket Approval to the Juveena Hydrogel System, a device developed by Rejoni, Inc. to reduce the formation and recurrence of intrauterine adhesions…
Siemens Healthineers unveiled the Accela radiotherapy system at ASTRO 2026, claiming multi-site SBRT in as little as 60 seconds. FDA 510(k) is pending.
The U.S. Food and Drug Administration has approved Atebrioz (zilurgisertib), a once-daily oral therapy developed by Mirum Pharmaceuticals, for the treatment of fibrodysplasia ossificans progressiva in patients aged 12 years…
Anthropic says Claude agents helped identify ART, a previously uncharacterized CRISPR-like repeat system in bacteriophages, after autonomously scanning 1.9 billion protein clusters, though the system's actual biological function remains unknown.
Anthropic and OpenEvidence are partnering to bring free, locally adapted clinical decision-support AI to doctors across roughly 100 low- and middle-income countries, building on pilot work in Rwanda and Botswana…